After complete resection, adjuvant therapy with imatinib for 3 years is the standard of care in patients with a high risk of recurrence (risk assessed by mitotic index, neoplasm size, anatomical site, and rupture of the tumor at the time of surgery) and KIT or PDGFR-α sensitive mutation [27]. This evidence concerns the gene KIT and neoplasm.